{
    "clinical_study": {
        "@rank": "20220", 
        "brief_summary": {
            "textblock": "The purpose of this study is to see if it is safe and effective to give Targretin capsules\n      to patients with AIDS-related Kaposi's sarcoma (KS)."
        }, 
        "brief_title": "A Study of Targretin Capsules in Patients With AIDS-Related Kaposi's Sarcoma", 
        "condition": [
            "Sarcoma, Kaposi", 
            "HIV Infections"
        ], 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome", 
                "Sarcoma, Kaposi", 
                "AIDS-Related Opportunistic Infections", 
                "Sarcoma"
            ]
        }, 
        "detailed_description": {
            "textblock": "This  is a multicenter, open-label study to evaluate the safety and efficacy of Targretin\n      capsules in patients with AIDS-related KS. NOTE: The daily dose may be reduced as necessary\n      for toxicity management."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Patients must have:\n\n          -  Serum HIV antibody positive by ELISA.\n\n          -  KS documented by biopsy (repeat biopsy is not required for entry if KS has been\n             previously confirmed histologically and the histopathology report has been reviewed).\n\n          -  A minimum of 6 mucocutaneous KS lesions, including at least 3 raised lesions, each of\n             which has been present for at least 30 days or has a longest dimension of at least\n             10mm, and has not received prior local or topical therapy within 60 days of study\n             entry.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following conditions or symptoms are excluded:\n\n          -  Concurrent, serious, uncontrolled infection including, but not limited to:\n\n          -  Mycobacterium avium intracellulare or other mycobacterium infection; Pneumocystis\n             carinii pneumonia; CMV retinitis or colitis; Toxoplasma brain abscess; Cryptococcal\n             meningitis.\n\n          -  Serious intercurrent illness or infection that would interfere with the ability of\n             the patient to carry out the treatment program.\n\n          -  Known allergy or sensitivity to retinoid class drugs.\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  Local or topical therapy such as, but not limited to, Vitamin A, tretinoin\n             (all-trans-retinoic acid), other retinoid class drugs, or intralesional (injection)\n             therapy to any KS indicator lesion.\n\n          -  Systemic anticancer chemotherapy, systemic anticancer hormonal therapy, and/or\n             systemic anticancer immunotherapy.\n\n          -  Systemic use of retinoid class drugs, beta-carotene compounds, or Vitamin A in doses\n             greater than 15,000 IU (5,000 mcg) per day (equivalent to approximately 3 times the\n             RDA) for any indication.\n\n          -  Human chorionic gonadotropin.\n\n        Concurrent Treatment:\n\n        Excluded:\n\n        Radiotherapy, cryotherapy, photodynamic therapy, and/or laser therapy for any KS indicator\n        lesion.\n\n        Prior Medication:\n\n        Excluded:\n\n          -  Systemic treatment of KS within 30 days of study entry.\n\n          -  Systemic treatment with either Vitamin A in doses greater than 15,000 IU (5,000 mcg)\n             per day (equivalent to approximately 3 times the RDA) or other retinoid class drugs\n             for any indication within 30 days of study entry.\n\n          -  Previous local or topical therapy of any KS indicator lesion such as, but not limited\n             to, Vitamin A, tretinoin (all-trans-retinoic acid), other retinoid class drugs, or\n             intralesional (injection) therapy within 60 days of study entry.\n\n        Prior Treatment:\n\n        Excluded:\n\n          -  Radiotherapy, cryotherapy, photodynamic therapy and/or laser therapy within 60 days\n             of study entry."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "27", 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002212", 
            "org_study_id": "287A", 
            "secondary_id": "L1069-21"
        }, 
        "intervention": {
            "intervention_name": "Bexarotene", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Anticarcinogenic Agents", 
                "Bexarotene"
            ]
        }, 
        "keyword": [
            "Sarcoma, Kaposi", 
            "Acquired Immunodeficiency Syndrome", 
            "Anticarcinogenic Agents"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Palm Springs", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92262"
                    }, 
                    "name": "Desert Univ School of Medicine"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New Orleans", 
                        "country": "United States", 
                        "state": "Louisiana", 
                        "zip": "70112"
                    }, 
                    "name": "Tulane Univ School of Medicine"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hershey", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "17033"
                    }, 
                    "name": "Milton S Hershey Med Ctr"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Phase II Evaluation of Targretin Capsules in Patients With AIDS-Related Kaposi's Sarcoma", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002212"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Ligand Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Safety Study, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 1999"
    }, 
    "geocoordinates": {
        "Desert Univ School of Medicine": "33.83 -116.545", 
        "Milton S Hershey Med Ctr": "40.286 -76.65", 
        "Tulane Univ School of Medicine": "29.951 -90.072"
    }
}